about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenPrognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.[Backstage of a massive open online course (MOOC) on cancer diagnosis].Centrosomal latency of incoming foamy viruses in resting cells.Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsHereditary renal cancer syndromes: an update of a systematic review.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.Foamy viruses--a world apart.Early stages of HIV replication: how to hijack cellular functions for a successful infection.Persistent infection with primate foamy virus type 1 increases human immunodeficiency virus type 1 cell binding via a Bet-independent mechanism.p53 in breast cancer subtypes and new insights into response to chemotherapy.Brief report: MET exon 14 alterations and new resistance-mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels.Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.p53 as an Effector or Inhibitor of Therapy Response.Cancer genomics guide clinical practice in personalized medicine.Chromatin tethering of incoming foamy virus by the structural Gag protein.Centrosomal pre-integration latency of HIV-1 in quiescent cells.Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.
P50
Q21092375-24A829A5-7E51-4D4C-B168-4CC9C238CA01Q27853006-60633554-211E-42ED-B977-3682BA763C67Q30235460-38A7EB3A-3F08-40CE-85BC-8802B1C0C6B3Q30489855-A90F2AEC-860E-4D8A-BAC2-846E05B0251DQ33285871-345BCE74-AEA6-45BE-9EF8-E65E927D80C7Q33573577-BFBF4D01-B5F5-4276-9FE0-2D8B7ED02E17Q33739841-1D5E155C-EA8C-44F0-81D0-E8AC5A244070Q33919243-9BC4EB6D-2CE7-4C35-B0E4-DED411B12E90Q34136090-B2D78759-1C7A-411F-BD1F-8266B4A1C915Q34855870-6B133E63-44BA-4D30-8C08-5C3F0E72919BQ35583968-63861E02-57EF-42E6-A99E-77C8A165E2BAQ35686908-17FB381A-61F9-4C16-B2E5-E0F1E7A90CB5Q35883042-DFDF2FB5-2E5E-4295-A25F-63E517C793BBQ36034380-1563B458-1F42-4255-9712-07023A237C28Q37568073-DB18DF9A-211E-4FFB-AC2A-4FC8A2855105Q38145813-D6A37C57-BC12-41EF-B170-9D7CCDCAA1ABQ38639160-94D76030-4CD2-4A51-A374-6D9A24FA1DD1Q38655004-D0F230CF-113F-4867-AFD9-89265A772B84Q38659283-2236C7F5-37A9-4FFD-9742-428276AF5F14Q39161048-1E740ECA-3648-4C43-B603-F1A0F3F1109BQ39961265-3CF7A04F-276E-44BF-83DC-3F4E61528AC8Q40082670-F8E7A87E-C185-46F1-AADF-5F9B9639BFC3Q40749266-245176A6-1ACB-4FE9-818C-99FC08E748C3
P50
description
onderzoeker
@nl
name
Jacqueline Lehmann-Che
@ast
Jacqueline Lehmann-Che
@en
Jacqueline Lehmann-Che
@es
Jacqueline Lehmann-Che
@sl
type
label
Jacqueline Lehmann-Che
@ast
Jacqueline Lehmann-Che
@en
Jacqueline Lehmann-Che
@es
Jacqueline Lehmann-Che
@sl
prefLabel
Jacqueline Lehmann-Che
@ast
Jacqueline Lehmann-Che
@en
Jacqueline Lehmann-Che
@es
Jacqueline Lehmann-Che
@sl